U.S. Markets open in 51 mins.

Prana Biotechnology Limited (PRAN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.26+0.02 (+0.89%)
At close: 4:00PM EDT
People also watch

Prana Biotechnology Limited

369 Royal Parade
Level 2
Parkville, VIC 3052
61 3 9349 4906

Full Time Employees12

Key Executives

Mr. Geoffrey Paul Kempler B.Sc, Grad.Dip.App.Soc.PsychCo-Founder, Exec. Chairman, Chief Exec. Officer and Managing Director363.79kN/A62
Ms. Kathryn Andrews B.Com, CPAChief Financial Officer102.04kN/A50
Ms. Dianne M. AngusChief Operating Officer283.22kN/A57
Dr. Rudolph Emile Tanzi Ph.D.Chief Scientific Advisor and Member of R&D Advisory BoardN/AN/AN/A
Dr. Steven D. Targum M.D.Chief Medical AdvisorN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2 for the treatment of Alzheimer’s and Huntington’s diseases; and PBT434 for the treatment of Parkinsonian movement disorders. The company is also developing PBT519 for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.

Corporate Governance

Prana Biotechnology Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.